Identification of novel modes of action and chemistry is a major focus of the collaboration.
Graffinity Pharmaceuticals entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets.
Amgen will gain access to Graffinity’s proprietary fragment-based drug discovery technology, which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets that play a key role in major human diseases. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.
